C4 Therapeutics board requires shareholder approval for stock option repricing

C4 Therapeutics, Inc.

Board approved Amendment No. 1 to the 2020 Stock Option and Incentive Plan on Oct 7, 2024.
Amendment requires stockholder approval for any reduction in exercise price or repricing of stock options or SARs.
Previous administrator authority to reprice without stockholder approval is removed.
Amendment is effective immediately and does not require stockholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.